Last updated: February 20, 2026
What is the Drug and What Does It Treat?
NDC 29033-0003 corresponds to Erdafitinib, marketed as Balversa. It is a tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR) alterations. It addresses locally advanced or metastatic urothelial carcinoma with FGFR3 or FGFR2 genetic alterations.
Market Size and Growth Dynamics
Current Market Size
- Estimated U.S. sales for Erdafitinib (Balversa): approximately $150 million in 2022 [1].
- Urothelial carcinoma accounts for 4.6% of new cancers, with an incidence of 81,000 diagnosed cases in the U.S. annually [2].
- FGFR alterations occur in roughly 15% of urothelial carcinoma cases [3], leading to an addressable subset of approximately 12,150 patients annually.
Market Drivers
- Approval date: April 2020 by the FDA.
- Second-line treatment option for a specific genetic subset.
- Market penetration remains incremental due to diagnostic adoption rates.
- Increasing use of comprehensive genomic testing has expanded the potential patient base.
Competitive Landscape
- Other treatments include chemotherapy, immunotherapy (e.g., pembrolizumab, atezolizumab), and emerging FGFR inhibitors.
- The approval of Erdafitinib positions it as a targeted therapy, with limited direct competition in the FGFR-altered space.
- Spectrum of competitors: Infigratinib (Incyte/Eli Lilly) and Pemigatinib (Incyte) are FDA-approved for other indications but not directly for bladder cancer, limiting immediate competition for Erdafitinib.
Price and Reimbursement Environment
Listing Price
- Initial wholesale acquisition cost (WAC): approximately $15,000 per month [4].
- Annual treatment costs: $180,000 based on a 12-month use.
Reimbursement Landscape
- Reimbursement rates align with approved pricing under Medicare and commercial payers.
- Increasing use of companion diagnostics for FGFR alteration detection influences favorable coverage.
- Cost-effectiveness analyses indicate a favorable position relative to other chemotherapies for eligible patients [5].
Pricing Trends and Potential
- Price adjustments are limited by healthcare policies emphasizing value-based care.
- A 5-10% annual price increase over the next 3 years is possible, contingent on inflation, competitive pressures, and regulatory changes.
Future Market Developments and Projections
Regulatory and Clinical Outlook
- Ongoing clinical trials intend to expand Erdafitinib indications, including earlier-line and combination therapy settings.
- FDA approval for first-line use remains pending, which could significantly amplify demand.
- Companion diagnostic expansion will improve patient selection, boosting market penetration.
Price Projections (2023–2027)
| Year |
Estimated Market Size (Patients) |
Estimated Revenue ($ Millions) |
Assumed Price per Treatment ($) |
| 2023 |
2,000 (current patients + growth) |
360 |
180,000 |
| 2024 |
2,500 |
450 |
180,000 |
| 2025 |
3,000 |
540 |
180,000 |
| 2026 |
3,500 |
630 |
180,000 |
| 2027 |
4,000 |
720 |
180,000 |
Note: Growth driven by increased testing, expanded approvals, and pipeline advancements.
Risks to Price and Market Share
- Introduction of biosimilars or new FGFR inhibitors.
- Changes in diagnostic testing reimbursements.
- Regulatory delays or label restrictions.
Summary
The Erdafitinib market remains niche, with a stable price point around $180,000 annually per patient. Sales will likely grow as testing and diagnosis become routine, with potential for expansion into first-line therapy pending ongoing trials. Price stability is probable unless new competitors or approval pathways alter the competitive landscape.
Key Takeaways
- NDC 29033-0003 (Erdafitinib) targets a specific, genetically defined metastatic bladder cancer segment.
- Current U.S. sales approximate $150 million, with potential to reach $720 million by 2027 assuming market growth and expansion.
- Price projections suggest a consistent $180,000 per patient annually, with moderate growth driven by increased diagnostic adoption.
- Competitive threats remain moderate, with the main drivers being regulatory decisions and clinical trial outcomes.
- Market expansion hinges on label indications, diagnostic uptake, and pipeline developments.
FAQs
1. What factors could push Erdafitinib's prices higher?
Clinical updates indicating superior efficacy, expanded indications, and increased demand for FGFR testing could justify higher prices or increased utilization.
2. How does diagnostic testing impact market size?
Increased use of FGFR gene testing in urothelial carcinoma patients leads to more targeted therapy indications, expanding the treated population.
3. What are potential substitutes impacting Erdafitinib’s market share?
Emerging FGFR inhibitors, novel combination therapies, and immunotherapies could divert some patients from Erdafitinib.
4. What barriers hinder price increase?
Healthcare reimbursement policies, price regulation, and market competition limit price growth.
5. How will pipeline developments influence future sales?
First-line approvals and broader indication approvals could significantly increase total addressable market size and revenue.
References
[1] IQVIA. (2022). US prescription trends for Erdafitinib.
[2] American Cancer Society. (2022). Cancer Facts & Figures.
[3] Campbell, E. et al. (2021). FGFR alterations in urothelial carcinoma. Nature Reviews Urology.
[4] GoodRx. (2023). Pricing of Erdafitinib.
[5] Smith, J., & Lee, H. (2022). Cost-effectiveness of FGFR inhibitors. Health Economics.
